Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database
-
- Kawada Kei
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
-
- Ishida Tomoaki
- Department of Pharmacy, Kochi Medical School Hospital
-
- Jobu Kohei
- Department of Pharmacy, Kochi Medical School Hospital
-
- Ohta Tsuyoshi
- Department of Neurosurgery, National Cerebral and Cardiovascular Center Hospital
-
- Fukuda Hitoshi
- Department of Neurosurgery, Kochi Medical School, Kochi University
-
- Morisawa Shumpei
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
-
- Kawazoe Tetsushi
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
-
- Tamura Naohisa
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
-
- Miyamura Mitsuhiko
- Graduate School of Integrated Arts and Sciences, Kochi University Department of Pharmacy, Kochi Medical School Hospital
この論文をさがす
説明
<p>Aggression is the most common adverse effect of antiepileptic drugs (AEDs). This study aimed to investigate the association of aggression with AED use. The reporting odds ratio (ROR) from adverse event reports, submitted to the Japanese Adverse Drug Event Report database between 2004 and 2020, was used to calculate and investigate the association between AEDs and aggression. We also analyzed the association of aggression with the combined use of AEDs and the relationship between AED-associated aggression and patient characteristics. A total of 433 patients developed aggression. Significant aggression signals were detected for perampanel (crude ROR: 325.04, 95% confidence interval (CI): 118.48–752.58, p < 0.01), levetiracetam (crude ROR: 17.14, 95% CI: 10.33–26.90, p < 0.01), lacosamide (crude ROR: 16.90, 95% CI: 2.02–62.51, p < 0.01), lamotrigine (crude ROR: 15.98, 95% CI: 9.99–24.39, p < 0.01), valproate (crude ROR: 6.68, 95% CI: 4.27–10.02, p < 0.01), and carbamazepine (crude ROR: 2.47, 95% CI: 1.17–4.59, p < 0.01). The combined therapy with perampanel and levetiracetam had a significant aggression signal (adjusted ROR: 25.90, 95% CI: 1.14–59.10, p < 0.01). In addition, we found that aggression frequently occurred in patients <60 year (adjusted ROR: 2.88, 95% CI: 1.49–5.56, p < 0.01) treated with levetiracetam. These results may be useful for minimizing the risk of aggression during the treatment of AEDs.</p>
収録刊行物
-
- Ｂｉｏｌｏｇｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ
-
Ｂｉｏｌｏｇｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ 45 (6), 720-723, 2022-06-01
公益社団法人 日本薬学会